Last month, tobacco control efforts found success in the UK, while US regulations faltered. Learn more in #ILCN : bit.ly/3WEZuv8 #LCSM

Register Today for #ACLC24 with a special Limited-Time Offer: Now through May 19th, use promo code ACLC50 at checkout to get US$50 off your registration rate! Not an #IASLC Member? Use the same promo code to get 50% off your 1st year membership fee! bit.ly/ACLC24Reg #LCSM

Registration is Open for #CTSS24 ! A premier event featured at #WCLC24 that offers a unique opportunity for healthcare professionals to engage in a day-long exploration of cutting-edge technologies & best practices in #lungcancer screening. Register: bit.ly/CTSS24 #LCSM

New in #ILCN : Drs. Laila Roisman and Nir Peled envision a future where AI facilitates fully personalized oncology. bit.ly/3y5N4SS #LCSM

Join the #IASLC & the Cancer Precision Medicine Commons (CPMC) for a 1-hr webinar on 5/22, focused on best practice recommendations for developing pt. education resources about biomarker testing & genetic testing for inherited cancer risk. Register: bit.ly/3WvSL6J #LCSM

Did you know the 9th #WCLC was held in Tokyo in 2000, the 10th in Vancouver in '03, the 11th in Barcelona in '05, the 12th in Seoul in '07 & the 13th in San Francisco in '09? A decade marked by highly successful WCLCs, w/more abstracts and participants every year! #LCSM #IASLC50

Stay on top of recent regulatory news with #ILCN , including FDA Oncology approval of adjuvant alectinib for resected ALK+ NSCLC: bit.ly/3JSQhbi #LCSM

Dive into groundbreaking data from the ALINA trial: Read a recent conversation with Drs. Ben Solomon and Narjust Florez, MD, FASCO from the Lung Cancer Considered podcast, via #ILCN : bit.ly/4b5XDUT #LCSM

Did you know, the number of JTO submissions & the quality of the manuscripts has increased year by year? In 2011, 28% of the submitted articles were from Europe, 27% from N. America & 43% from Asia/Australia. JTO’s initial Impact Factor was 3.5 and is currently 20.4! #IASLC50

Analysis in #ILCN : Drs. @christianrolfo and VCDenninghoff look at the current state of precision medicine in #lungcancer treatment and how to achieve further improvements in survival. bit.ly/4bvB5MO #LCSM

Drs. Tanizaki, Nakazawa & Tachihara, members of the #IASLC Equity Taskforce, emphasize the importance of participating in the IASLC Global Survey on Inclusivity to enhance our comprehension of the varied needs within our diverse global membership. gather.video/fSnz #LCSM

We are now accepting applications for groups of qualified #IASLC members from the Asia/ROW Region, to serve as Co-Chairs for the 2026 World Conference on Lung Cancer, taking place Sept. 12-15, 2026 in Seoul, South Korea. Learn More & Apply Today: bit.ly/3Qsj9ew #LCSM

The Call for Abstracts & Registration are now open for #LALCA24 in Bogota, Colombia, Nov. 14-16, 2024. You will network across disciplines w/experts focused on thoracic malignancies, & learn the latest developments in prevention, detection & care! bit.ly/LALCA24-Reg #LCSM

In 2006, there were 9 issues of the Journal of Thoracic Oncology, & monthly issues began in 2007. JTO was then accepted by the National Library of Medicine for listing in MEDLINE & Pub Med. Over the years, many editors have been published in several different languages! #IASLC50

Join the #IASLC & the Cancer Precision Medicine Commons (CPMC) for a 1-hr webinar on 5/22, focused on best practice recommendations for developing pt. education resources about biomarker testing & genetic testing for inherited cancer risk. Register: bit.ly/3WvSL6J #LCSM

Your Perspective Matters! Your Impact Counts! Join us in shaping a more inclusive & welcoming #IASLC community! Share your feedback on the global survey on inclusivity, where every voice counts. Take the survey & be the change you wish to see! bit.ly/DEISurvey24

In this #LungCancerConsidered episode, Narjust Florez, MD, FASCO moderates a discussion about adenosquamous cell carcinoma of the lung, covering diagnosis, treatment & outcomes in this group of patients. W/guests Dr Riyaz Shah & Dr. Lynette Sholl. Listen Now: bit.ly/2worlds24 #LCSM

Stay on top of regulatory news with #ILCN , including FDA Oncology accelerated approval of T-DXd for unresectable or metastatic HER2-positive solid tumors. bit.ly/44p1ObO #LCSM